Program
inclisiran
Also written as “Inclisiran”, “Inclisiran Sodium” and “ALN-PCSSC”.
Its studies are mostly in Hypercholesterolemia · Atherosclerosis · Homozygous Familial Hypercholesterolemia · Acute Coronary Syndrome · Hyperlipoproteinemia Type II, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 3615 open or running | phase 4since Dec 13, 2021 | Nov 3, 2015 | Nov 27, 2026phase 4 · NCT06501443 |
| Alnylam Pharmaceuticals | 10 open or running | phase 1since Dec 5, 2014 | Dec 5, 2014 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 20 studies since Dec 5, 2014.
- Apr 29, 2022Phase 3 study in Coronary Artery DiseaseNovartis · NCT05360446 · 610 enrolled · United States, Argentina, Australia and more
- Dec 27, 2022Phase 3 study in Homozygous Familial HypercholesterolemiaNovartis · NCT05682378 · 195 planned · United States, Argentina, Brazil and more
- Feb 13, 20232 phase 3 studiesNovartis · NCT05739383, NCT05763875
- May 24, 2023Phase 3 study in AtherosclerosisNovartis · NCT05888103 · 207 enrolled · China
- Apr 15, 20243 phase 4 studiesNovartis · NCT06372925, NCT06386419, NCT06431763
- Jun 21, 2024Phase 4 study in HypercholesterolemiaNovartis · NCT06501443 · 520 planned · Argentina, Brazil
- Sep 11, 20242 phase 3 studiesNovartis · NCT06597019, NCT06597006
- Feb 3, 2025Phase 3 study in AtherosclerosisNovartis · NCT06813911 · 246 enrolled · United States, China, France and more
- Mar 6, 2025Phase 4 study in Coronary DiseaseNovartis · NCT06941792 · 1,590 enrolled · China
- Jul 31, 2025Phase 3 study in Acute Coronary SyndromeNovartis · NCT07102628 · 300 planned · Argentina, Australia, Canada and more
- May 20, 2026Phase 2 study in HypercholesterolemiaNovartis · NCT07610278 · 120 planned · United States
- May 29, 2026Phase 1 study in Inclisiran FormulationNovartis · NCT07626281 · 152 planned · United States
- Jun 29, 2026Phase 4 study in Acute Coronary SyndromeNovartis · NCT07684469 · 300 planned
- Oct 30, 2026Primary completion moved from 2027-02-28 to 2028-02-29Date moved laterphase 4 · +12 months · NCT07684469
Ahead
- Nov 27, 2026Primary completion: phase 4 study in HypercholesterolemiaNovartis · NCT06501443
- Dec 21, 2026Primary completion: phase 1 study in Inclisiran FormulationNovartis · NCT07626281
- Dec 30, 2026Primary completion: phase 4 study in Plaque, AtheroscleroticNovartis · NCT06372925
- Feb 11, 2027Primary completion: phase 3 study in Acute Coronary SyndromeNovartis · NCT07102628
TargetBeta
“The present clinical trial adopted inclisiran, a PCSK9 inhibitor with well-documented clinical safety and robust lipid-lowering effects, in combination with amlodipine besylate.”study text, by rule · the study
Other programs on PCSK9
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| alirocumabrule | Sanofi | phase 4 | 48 |
| evolocumabrule | Amgen | phase 4 | 45 |
| lerodalcibeprule | lib-therapeutics-llc | phase 3 | 14 |
| tafolecimabrule | Innovent Biologics | phase 3 | 8 |
| recaticimabrule | Jiangsu HengRui Medicine | phase 3 | 7 |
| QLC7401rule | Qilu Pharmaceutical | phase 3 | 5 |
| SAL003rule | Shenzhen Salubris Pharmaceuticals | phase 3 | 3 |
| VERVE-102 | Eli Lilly | phase 2 | 2 |
| DNV001rule | hangzhou-dinovate-biotech-co-ltd | phase 2 | 1 |
| RBD7022rule | Qilu Pharmaceutical | phase 1 | 2 |
Studies
All 37 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07684469Acute Coronary Syndrome | 4 | Not yet recruiting | Novartis | Feb 29, 2028 | 300 |
| NCT07626281Inclisiran Formulation · United States | 1 | Recruiting | Novartis | Dec 21, 2026 | 152 |
| NCT07610278Hypercholesterolemia · United States | 2 | Recruiting | Novartis | Apr 28, 2027 | 120 |
| NCT07102628Acute Coronary Syndrome · Argentina, Australia, Canada and more | 3 | Recruiting | Novartis | Feb 11, 2027 | 300 |
| NCT06941792Coronary Disease · China | 4 | Active, not recruiting | Novartis | Apr 30, 2027 | 1,590 |
| NCT06813911Atherosclerosis · United States, China, France and more | 3 | Active, not recruiting | Novartis | Feb 3, 2028 | 246 |
| NCT06597019Hyperlipoproteinemia Type II · United States, Argentina, Austria and more | 3 | Recruiting | Novartis | Mar 21, 2028 | 60 |
| NCT06597006Homozygous Familial Hypercholesterolemia · United States, Austria, China and more | 3 | Recruiting | Novartis | Mar 21, 2028 | 9 |
| NCT06501443Hypercholesterolemia · Argentina, Brazil | 4 | Recruiting | Novartis | Nov 27, 2026 | 520 |
| NCT06431763Hypercholesterolemia · Germany | 4 | Completed | Novartis | Dec 1, 2025 | 402 |
| NCT06386419Primary Hypercholesterolemia · India | 4 | Completed | Novartis | Jan 13, 2026 | 65 |
| NCT06372925Plaque, Atherosclerotic · China | 4 | Active, not recruiting | Novartis | Dec 30, 2026 | 318 |
| NCT05888103Atherosclerosis · China | 3 | Completed | Novartis | Apr 2, 2024 | 207 |
| NCT05763875Hypercholesterolemia · United States, Colombia, Germany and more | 3 | Completed | Novartis | Jun 20, 2024 | 350 |
| NCT05739383Cardiovascular Diseases · United States, Argentina, Australia and more | 3 | Active, not recruiting | Novartis | Apr 16, 2029 | 14,012 |
| NCT05682378Homozygous Familial Hypercholesterolemia · United States, Argentina, Brazil and more | 3 | Recruiting | Novartis | Mar 25, 2032 | 195 |
| NCT05360446Coronary Artery Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | Novartis | Oct 26, 2026 | 610 |
| NCT05192941Hypercholesterolemia · Bulgaria, Czechia, Estonia and more | 4 | Completed | Novartis | Jun 11, 2024 | 1,770 |
| NCT05030428Atherosclerosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Novartis | May 10, 2027 | 17,004 |
| NCT04929249Atherosclerosis · United States | 3 | Completed | Novartis | Sep 15, 2023 | 450 |
| NCT04873934Acute Coronary Syndrome · United States | 3 | Completed | Novartis | Aug 7, 2024 | 400 |
| NCT04807400Atherosclerosis · United Kingdom | 3 | Completed | Novartis | Jan 13, 2023 | 892 |
| NCT04774003Hyperlipidemias · China | 1 | Completed | Novartis | Oct 18, 2021 | 40 |
| NCT04765657Hypercholesterolemia · China, Singapore, South Korea and more | 3 | Active, not recruiting | Novartis | Jun 9, 2022 | 345 |
| NCT04666298Hypercholesterolemia · Japan | 2 | Completed | Novartis | Apr 18, 2022 | 312 |
| NCT04659863Homozygous Familial Hypercholesterolemia · United States, Canada, France and more | 3 | Completed | Novartis | Oct 30, 2023 | 13 |
| NCT04652726Familial Hypercholesterolemia - Heterozygous · United States, Argentina, Brazil and more | 3 | Completed | Novartis | Nov 9, 2023 | 141 |
| NCT03851705Homozygous Familial Hypercholesterolemia · Hong Kong, Israel, Russian Federation and more | 3 | Completed | Novartis | Mar 2, 2020 | 56 |
| NCT03814187Hypercholesterolemia · United States, Canada, Czechia and more | 3 | Completed | Novartis | Feb 13, 2023 | 3,275 |
| NCT03400800Hypercholesterolemia · Czechia, Germany, Hungary and more | 3 | Completed | Novartis | Jul 31, 2019 | 1,617 |
| NCT03399370Hypercholesterolemia · United States | 3 | Completed | Novartis | Sep 10, 2019 | 1,561 |
| NCT03397121Hypercholesterolemia · United States, Canada, Czechia and more | 3 | Completed | Novartis | Aug 27, 2019 | 482 |
| NCT03159416Renal Insufficiency · New Zealand | 1 | Completed | Novartis | Mar 24, 2018 | 31 |
| NCT03060577Atherosclerosis · United States, Canada, Germany and more | 2 | Completed | Novartis | Dec 17, 2021 | 382 |
| NCT02963311Homozygous Familial Hypercholesterolemia · United States, Netherlands, South Africa | 2 | Completed | Novartis | Oct 8, 2018 | 9 |
| NCT02597127Atherosclerosis · United States, Canada, Germany and more | 2 | Completed | Novartis | Jun 7, 2017 | 501 |
| NCT02314442Hypercholesterolemia · United Kingdom | 1 | Completed | Alnylam Pharmaceuticals | May 2015 | 70 |
How it is read
Names in the registry
- “Inclisiran”, 16 entries
- “Inclisiran Sodium”, 4 entries
- “inclisiran”, 3 entries
- “ALN-PCSSC”, 3 entries
- “Inclisiran sodium 300 mg”, 2 entries
Conditions, from the studies’ own filings
- Hypercholesterolemia, 13 studies
- Atherosclerosis, 7 studies
- Homozygous Familial Hypercholesterolemia, 5 studies
- Acute Coronary Syndrome, 3 studies
- Hyperlipoproteinemia Type II, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.